Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Wockhardt USA LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Evaluate the Effect of WCK 5222 on the QT/QTc Interval in Healthy Volunteers

Phase 1

Completed

Conditions: QT/QTc Interval in Healthy Volunteers

Interventions: Drug: WCK 5222
Drug: IV placebo matched to WCK 5222 / Moxifloxacin IV solution
Drug: Moxifloxacin 400-mg

First Posted Date: 2018-06-13

Last Posted Date: 2018-06-13

Lead Sponsor: Wockhardt

Target Recruit Count: 60

Registration Number: NCT03554304

Locations: 🇺🇸
Spaulding Clinical Research, West Bend, Wisconsin, United States

Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Phase 3

Completed

Conditions: Acute Bacterial Skin and Skin Structure Infections

Interventions: Drug: Oral Levonadifloxacin/Linezolid Tablet
Drug: Intravenous Levonadifloxacin/Linezolid Infusion

First Posted Date: 2018-01-19

Last Posted Date: 2020-06-29

Lead Sponsor: Wockhardt

Target Recruit Count: 501

Registration Number: NCT03405064

Locations: 🇮🇳
Osmania General Hospital, Hyderabad, Andhra Pradesh, India
🇮🇳
Government General Hospital (Associated by Government Siddhartha Medical College), Vijayawada, Andhra Pradesh, India
🇮🇳
Sanjivani Superspeciality Hospital Pvt. Ltd., Ahmedabad, Gujarat, India

and more 29 locations

To Investigate The Pharmacokinetics Of Intravenous WCK 5222 (FEP-ZID) In Patients With Renal Impairment

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: WCK 5222

First Posted Date: 2016-10-24

Last Posted Date: 2018-08-02

Lead Sponsor: Wockhardt

Target Recruit Count: 48

Registration Number: NCT02942810

Locations: 🇺🇸
University of Miami,Division of Clinical Pharmacology, Miami, Florida, United States

Phase II Study of Oral Nafithromycin in CABP

Phase 2

Completed

Conditions: Community-Acquired Bacterial Pneumonia (CABP)

Interventions: Drug: Moxifloxacin 400 mg
Drug: Nafithromycin 800 mg 5 days
Drug: Nafithromycin 800 mg 3 days

First Posted Date: 2016-09-16

Last Posted Date: 2019-12-20

Lead Sponsor: Wockhardt

Target Recruit Count: 231

Registration Number: NCT02903836

Locations: 🇺🇸
Empire Clinical Research, LLC, Miami Lakes, Florida, United States
🇺🇸
A & L Clinical research, Miami, Florida, United States
🇺🇸
A Plus Research Inc., Miami, Florida, United States

and more 3 locations

A Phase 1 Pharmacokinetic Study of Single-Ascending Doses of Intravenous Nafithromycin in Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Placebo
Drug: Nafithromycin

First Posted Date: 2016-05-12

Last Posted Date: 2018-08-01

Lead Sponsor: Wockhardt

Target Recruit Count: 60

Registration Number: NCT02770404

Locations: 🇺🇸
Phase 1 unit : Spaulding Clinical Research, LLC, West Bend, Wisconsin, United States

A Single-dose Study to Investigate the Pharmacokinetics of Intravenous FEP-TAZ in Patients With Renal Impairment

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: Cefepime and Tazobactam combination

First Posted Date: 2016-03-16

Last Posted Date: 2016-08-26

Lead Sponsor: Wockhardt

Target Recruit Count: 48

Registration Number: NCT02709382

Locations: 🇺🇸
University of Miami,Division of Clinical Pharmacology, Miami, Florida, United States

MED Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous WCK 5222 (Zidebactam and Cefepime) in Healthy Volunteers

Phase 1

Completed

Conditions: Serious Gram-negative Infections

Interventions: Drug: Placebo
Drug: Intravenous infusions of WCK 5222

First Posted Date: 2016-03-14

Last Posted Date: 2016-08-04

Lead Sponsor: Wockhardt

Target Recruit Count: 20

Registration Number: NCT02707107

Locations: 🇺🇸
Quintiles, Overland Park, Kansas, United States

MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous Zidebactam in Healthy Adults

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Placebo
Drug: 3 g or 6 g Zidebactam

First Posted Date: 2016-02-04

Last Posted Date: 2016-08-04

Lead Sponsor: Wockhardt

Target Recruit Count: 21

Registration Number: NCT02674347

Locations: 🇺🇸
Quintiles, Overland Park, Kansas, United States

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WCK 5107 Alone and in Combination With Cefepime

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: WCK 5107 250 mg to 2000 mg
Drug: Placebo
Drug: Cefepime 2000 mg
Drug: WCK 5107 1000/2000 mg with Cefepime 2000 mg combination

First Posted Date: 2015-08-25

Last Posted Date: 2016-05-03

Lead Sponsor: Wockhardt

Target Recruit Count: 88

Registration Number: NCT02532140

Locations: 🇺🇸
Quintiles, Overland Park, Kansas, United States

Study to Determine and Compare Plasma and Intrapulmonary Concentrations of WCK 4873 in Healthy Adult Human Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: WCK 4873

First Posted Date: 2015-05-25

Last Posted Date: 2015-08-03

Lead Sponsor: Wockhardt

Target Recruit Count: 36

Registration Number: NCT02453529

Locations: 🇺🇸
Pulmonary Associates, 1112 E. McDowell Rd., Phoenix, Arizona, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy